900 WEST PLATT STREET, SUITE 200, TAMPA, FL
Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
Andriy Mushak Appointed Fractional CFO; Alan Weichselbaum Departs
Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson’s Disease Study
Other Events
Telomir Pharmaceuticals Acquires TELI Pharmaceuticals for 34.4M Shares
Q2
Q1
FY 2025
Q3
FY 2023
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(4)
Certificate
Registration of Securities
Amended Registration Statement for Securities
Additional Proxy Materials
Definitive Proxy Statement
Definitive Merger Proxy Statement
PRER14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
PREM14A
Prospectus Filed Pursuant to Rule 424(b)(1)
Correspondence
Submission Upload